Stock Analysis of Abcellera Biologics Inc (ABCL) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABCL
Close 4.64
Change -0.190 / 3.93 %
Volume 1839.88 K
Vol Change -212116.00 / 10.34 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Excellent Growth
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Abcellera Biologics Inc
PE (TTM)

-10.61

Very Poor
Price / Book

1.62

Good
Price / Sales

27.19

Very Poor
Piotroski F Score

7.0

Very Good
Market Cap

1346.39 M

Enterprise Value

965436 K

ROA (TTM)

-11.15

Very Poor
ROE (TTM)

-10.64

Very Poor
Net Margin (TTM)

-256.27

Very Poor
Revenue

4080.53 %

485424 K
Net Profit

7270.55 %

158519 K
Debt to Equity

0.0045

Excellent
Altman Z Score

4.56

Very Good
Quick Ratio

8.65

Excellent
Cash Ratio

7.49

Excellent


Highs/Lows of Abcellera Biologics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week4.53 2.43 % 0.247 % 5.024.429-Nov-2328-Nov-23
Two Week4.6 0.870 % 0.314 % 5.024.27529-Nov-2327-Nov-23
One Month4.7 1.28 % 4.67 % 5.023.8929-Nov-2310-Nov-23
Three Month5.59 16.99 % 1.02 % 5.793.8705-Sep-2330-Oct-23
Six Months6.79 31.66 % 6.52 % 8.053.8719-Jul-2330-Oct-23
One year12.71 63.49 % 12.03 % 12.723.8705-Dec-2230-Oct-23
Two year14.02 66.90 % 0.512 % 10.063.8716-Feb-2330-Oct-23


Technical View of Abcellera Biologics Inc
RSI

33.06

Neutral
MACD

-0.228

Bullish
ADX

32.21

Mild Bearish
Super Trend

4.65

Mild Bearish
Williams %R

-100.00

Mild Bullish
CCI

-192.54

Mild Bearish


EMA 5

4.11

Strong Bearish
EMA 15

4.28

Mild Bearish
EMA 50

4.89

Strong Bearish
EMA 100

5.63

Strong Bearish
SMA 100

5.90

Strong Bearish
SMA 200

6.94

Strong Bearish
SMA 5 / 20

4.17 / 4.31

Strong Bearish
SMA 15 / 50

4.27 / 4.88

Mild Bearish
SMA 50 / 200

4.88 / 6.94

Strong Bearish




Charts of Abcellera Biologics Inc


Returns of Abcellera Biologics Inc with Peers
Period / StockABCLTNDMMRUSIRON
1 Week2.43%8.99%-2.56%4.18%
1 Mth-1.28%34.73%-5.18%14.22%
3 Mth-16.99%-23.81%1.59%5.90%
6mth-31.66%-14.33%7.47%36.71%
1 Year-63.49%-50.36%57.58%223.26%
2 Year-66.90%-84.09%-4.38%132.64%
5 Years-39.80%98.24%


Compare Fundamentals of Abcellera Biologics Inc with Peers
Ratio / StockABCLTNDMMRUSIRON
PE-10.61-6.58-1550.28-15.87
P/B1.623.72968.874.67
ROA-11.15-21.09-44.50-27.95
ROE-10.64-56.53-62.50-29.45
Debt To Equity0.00450.6740.00680.0017
Revenue485424 K
4080.53 % 		801217 K
14.00 % 		29604.00 K
39.72 % 		0
%
Net Income158519 K
7270.55 % 		-94594.00 K
707.70 % 		-131194.00 K
96.35 % 		-46090.00 K
35.87 %


Technicals of Abcellera Biologics Inc with Peers
Technical / StockABCLTNDMMRUSIRON
ADX24.6022.4615.2820.52
CMF0.0850.1670.0750.061
MFI62.2672.6148.6586.50
RSI54.1266.2050.9566.06
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MATrueTrueTrueTrue
Price Above 200 MAFalseFalseTrueTrue


About : Abcellera Biologics Inc

Address : 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
Tel : 604 559 9905
URL : https://www.abcellera.com
Code : ABCL, ISIN : CA00288U1066, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 11_Dec_2020
Employee Count : 630

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.


Note : All Data Generated at the End of Trading Hours (EOD Data)